Navigation Links
Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round
Date:2/3/2010

GENEVA, February 3 /PRNewswire/ -- Viroblock SA, a start-up dedicated to developing and commercializing a new generation of anti-viral products, today announced that Dr. Jamie Paterson will join Viroblock as Chief Executive Officer (CEO).

Jamie Paterson, a British national, can look back at 20 years of experience in the pharmaceutical industry. Prior to joining Viroblock he was Chief Commercial Officer at Neurim Pharmaceuticals. During his 18 years at Procter & Gamble he held several positions with increasing responsibility including Marketing Manager Italy and Commercial Director Spain. His final position at P&G was European Director of Strategic Planning and New Business Development - Rx & OTC. Jamie holds a PhD in Biochemistry from Imperial College, University of London.

"I welcome Jamie as our new CEO and I am pleased to concentrate my activities to further demonstrate scientifically the potential of our technology in several viral indications" said Thierry Pelet who is one the co-founders of the company. Thierry will assume the position of Chief Science Officer (CSO).

Viroblock further announced that it has completed its second round of equity funding. The Series B financing round was led by Fongit Seed Invest SA. Peter Pfister, Initiative Capital Romandie SA (managed by DEFI Gestion) and BlueOcean Ventures acted as co-investors.

"With Jamie and Thierry we have a strong leadership team with proven business skills and accomplished scientific know-how. This team equipped with the additional funding can now start developing our first anti-viral products, which will bring the company to the next level, said Peter Pfister, Chairman of the Board.

About Viroblock

Viroblock is dedicated to developing and commercializing a new generation of anti-viral products with a novel mechanism of action against enveloped viruses. Enveloped viruses represent more than 60% of all existing viruses and include major human pathogens such as human and avian influenzas, the hepatitis B and C viruses and the AIDS virus.

Viroblock's unique proprietary products and technologies open very promising opportunities in a number of prophylactic and therapeutic applications.

Viroblock was founded in October 2005 by the late Donald Wallach, a scientist and academic with past tenure at the Harvard Medical School and Tufts University, and a pioneer in the research of liposome systems.

    For more information:

    Thierry Pelet
    +41-22-884-8344
    info@viroblock.com


SOURCE Viroblock SA


'/>"/>
SOURCE Viroblock SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray
2. CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner
3. Professional Reprographics Hires Recent Cal Poly Grad to Join their Team
4. Zeus Expands International Support With New Hires
5. Derma Sciences, Inc. Hires the Investor Relations Group
6. Mirixa Corporation Announces Key New Hires
7. Oppenheimer Announces the Addition of Several Recent Senior Hires in Investment Banking
8. Campbell Alliance Hires Joe Dillon, Expands Business Development Practice
9. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
10. Bio-Matrix Scientific Group Announces New Hires to Management Team
11. Artemis Health Hires Richard Rava, Ph.D., as Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , ... January 16, 2017 , ... ... laws precedential publication its decision on the appeal filed by India-based Dishman Pharmaceutical ... breach of contract against DPCL and one of its Dishman Group’s 100% wholly ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today ... will allow more customers to receive their primers in ... or compromise in quality found with other providers. Express ... United States at no additional fee. ... routine genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, ...
(Date:1/13/2017)... , Jan 13, 2017 Research and ... Product, Manufacturing, Application - Global Forecast to 2021" report to ... ... 2021 from USD 3.39 Billion in 2016, at a CAGR of ... the basis of product, manufacturing type, and application. Factors such as ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... that it has found among its diverse customer base. The latest entry in ... most brands electroporators including BTX and Bio-Rad. FireflySci is introducing three distinct varieties ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition ... Service, Application Area, End User, And Region - Global Forecast to 2021", published ... in 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... of €500.0 million principal amount of its 1.414% senior unsecured ... 2.425% senior unsecured notes due 2026. The ... 2016, subject to the satisfaction of customary closing conditions.  The ... The Company intends to use the net ...
Breaking Biology News(10 mins):